Research

Hormonal

Tirzepatide (5 mg, 10 mg, and 15 mg) significantly reduces body weight in patients with type 2 diabetes and obesity compared to placebo, GLP-1 receptor agonists, and basal insulin.

Tirzepatide is a highly effective treatment for weight loss in people with T2DM or obesity, outperforming other common medications like GLP-1 agonists and insulin. It is taken as a once-weekly injection. While it causes gastrointestinal side effects like nausea and diarrhea, these are usually mild and temporary. If you are considering this, discuss the benefits of significant weight loss against the potential for temporary stomach issues with your doctor.

GoodSupportsHIGH confidence
In total, ten studies (12 reports) involving 9,873 patients were identified. A significant loss body weight in the tirzepatide group versus the placebo by -9.81 kg (95% CI (-12.09, -7.52), GLP-1 RAs by -1.05 kg (95% CI (-1.48, -0.63), and insulin by -1.93 kg (95% CI (-2.81, -1.05), respectively.
Fei Lin et al. · PLoS ONE · 2023

Why this rating

Based on a meta-analysis of 10 RCTs involving nearly 10,000 patients, though heterogeneity was high in some comparisons.

Source

Weight loss efficiency and safety of tirzepatide: A Systematic review

Fei Lin et al. · PLoS ONE · 2023

DOI 10.1371/journal.pone.0285197

Meta-analysis · 10 studiesCited 51×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →